Neutralizing Antibodies Against Interferon-Beta ... - KoreaMed Synapse

0 downloads 0 Views 827KB Size Report
Nov 2, 2017 - treated with subcutaneous IFN-β-1b, 9 of the 60 (15%) who were ... IFN-β-1a, and 0 of the 5 (0%) who were treated with intramuscular IFN-β-1a.
JCN

ORIGINAL ARTICLE

Open Access

pISSN 1738-6586 / eISSN 2005-5013 / J Clin Neurol 2018;14(2):186-190 / https://doi.org/10.3988/jcn.2018.14.2.186

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis Jae-Won Hyuna, Gayoung Kimb Yeseul Kimb, Byungsoo Kongb AeRan Jounga, Na Young Parka Hyunmin Janga Hyun-June Shina, Su-Hyun Kima Suk-Won Ahnc, Ha Young Shind So-Young Huhe, Woojun Kimf Min Su Parkg, Byung-Jo Kimh Byoung Joon Kimi Jeeyoung Ohj, Ho Jin Kima,b a

Department of Neurology & Division of Clinical Research, Research Institute and Hospital of National Cancer Center, Goyang, Korea c Department of Neurology, Chung-Ang University College of Medicine, Seoul, Korea d Department of Neurology, Yonsei University College of Medicine, Seoul, Korea e Department of Neurology, Kosin University College of Medicine, Busan, Korea f Department of Neurology, College of Medicine, Catholic University, Seoul, Korea g Department of Neurology, Yeungnam University College of Medicine, Daegu, Korea h Department of Neurology, Korea University College of Medicine, Seoul, Korea i Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea j Department of Neurology, Konkuk University School of Medicine, Seoul, Korea b

Received September 19, 2017 Revised November 2, 2017 Accepted November 2, 2017

Correspondence Ho Jin Kim, PhD Department of Neurology, Research Institute and Hospital of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea Tel +82-31-920-2438 Fax +82-31-905-5524 E-mail [email protected]

186

Background and Purpose Patients treated with interferon-beta (IFN-β) can develop neu-

tralizing antibodies (NAbs) against IFN-β that can negatively affect the therapeutic response. This study assessed the prevalence of NAbs and the impact of NAb positivity on the therapeutic response to IFN-β in Korean patients with multiple sclerosis (MS).

Methods This was a multicenter study involving 150 MS patients from 9 Korean medical centers who were treated with IFN-β for at least 6 months. Sera that had not been influenced by acute treatment were assessed for NAbs using a luciferase reporter gene assay. To evaluate the association between persistent positivity for NAbs and disease activity, NAbs were tested at 2 different time points in 75 of the 150 patients. Disease activity was defined as the presence of clinical exacerbations and/or active MRI lesions during a 1-year follow-up after NAb positivity was confirmed.

Results NAbs were found in 39 of the 150 (26%) MS patients: 30 of the 85 (35%) who were treated with subcutaneous IFN-β-1b, 9 of the 60 (15%) who were treated with subcutaneous IFN-β-1a, and 0 of the 5 (0%) who were treated with intramuscular IFN-β-1a. Thirty of the 39 patients exhibiting NAb positivity were tested at different time points, and 20 of them exhibited persistent NAb positivity. Disease activity was observed more frequently in patients with persistent NAb positivity than in those with transient positivity or persistent negativity [16/20 (80%) vs. 4/55 (7%), respectively; p